Proteogenomic Translational Research Centers for Clinical Proteomic Tumor Analysis Consortium (U01) -- Deadlines Extended

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) is a part of the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC). This reissuance of the CPTAC program leverages recent advancements in cancer proteomics and genomics and accelerates research in these areas by disseminating research resources for the scientific community. The program will support broad efforts focused on several cancer types to explore further the complexities of cancer proteomes and their connections to abnormalities in cancer genomes. The potential of proteomic and proteogenomic approaches will also be explored in translational research focused on clinically-relevant problems, such as the ability to predict which treatments are likely to be effective against a specific patient's tumor.

This FOA solicits applications for multidisciplinary Proteogenomic Translational Research Centers (PTRCs). PTRCs are intended to function as an interactive group focused on applying standardized state-of-the-art proteomic and genomic approaches to clinically-relevant research projects. The projects should focus on the proteogenomic aspects in understanding drug responses and resistance to therapies in a clinical context. The proposed projects are expected to be conducted in collaboration with clinical researchers and use human biospecimens from clinical trials. The projects should also involve the use of relevant preclinical models of cancer. Proposed projects are expected to integrate comprehensive proteomics data with genomics data. It is envisioned that these projects will facilitate a rational approach to target cancer related pathways and improve outcomes for patients with cancer.

PTRCs will interact with additional CPTAC sub-programs that include:

  • Proteogenomic Data Analysis Centers (PGDACs, to be supported by RFA-CA-15-023) that will conduct integrative analyses of data across the entire proteomes and genomes of cancer types of focus to elucidate how distinct changes at the proteome level are related to abnormalities in cancer genomes and/or changes at the functional level; and
  • Proteome Characterization Centers (PCCs, to be supported by RFA-CA-15-021) that will use various standardized proteomic analysis technologies for the systematic and comprehensive proteome-wide characterization of defined sets of genomically-characterized samples. These samples (human biospecimens, cultured cells, and animal cancer models) will be provided by the NCI.


  • Letter of Intent Due Date(s): 30 days prior to application due date
  • Application Due Date(s): New Date May 11, 2016 per issuance of NOT-CA-16-004. (Original Date: January 27, 2016)

​RFA-CA-15-022 Expiration Date New Date May 12, 2016 per issuance of NOT-CA-16-004. (Original Expiration Date: January 28, 2016)

Agency Website

Eligibility Requirements

This FOA requires applications with more than one PD/PI, or multiple PDs/PIs, designated due to the "team science" approach of the projects.  Applications must designate at least two PDs/PIs: one expert in proteomics and another expert in clinical trials..

An individual designated as a PD/PI on an application in response to the PGDAC FOA, RFA-15-023, cannot be designated as a PD/PI under this FOA. However, an individual designated as a PD/PI on an application in response to the PCC FOA (RFA-CA-15-021) can be designated as a PD/PI under this FOA.



Amount Description

Application budgets for each Center may not exceed $910,000 in direct costs per year and need to reflect the actual needs of the proposed project. 

Applicants may request up to 5 years of support.


Funding Type





Environmental & Life Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

May 11, 2016